Median Overall Survival of First-Line Treatments for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

Tanios S. Bekaii-Saab

Median Overall Survival of First-Line Treatments for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

Interview with the Innovators

Pancreatic Cancer Patient Education

Videos

Featuring:

Tanios S. Bekaii-Saab, MD

David F. and Margaret T. Grohne Professor of Novel Therapeutics for Cancer Research
Chair and Consultant, Division of Hematology and Medical Oncology
Professor, Mayo Clinic College of Medicine and Science, Scottsdale, AZ

Shubham Pant, MD

Professor, GI Medical Oncology
MD Anderson Cancer Center, Houston, TX

Michael Pishvaian, MD, PhD

Associate Professor of Oncology
Johns Hopkins University, Washington, DC

In this second installment, Shubham Pant, MD, along with Tanios Bekaii-Saab, MD, discuss various first-line treatments for metastatic pancreatic ductal adenocarcinoma from the MPACT, PRODIGE-4, and NAPOLI 3 trials.

Featuring:

Tanios S. Bekaii-Saab, MD

David F. and Margaret T. Grohne Professor of Novel Therapeutics for Cancer Research
Chair and Consultant, Division of Hematology and Medical Oncology
Professor, Mayo Clinic College of Medicine and Science, Scottsdale, AZ

Shubham Pant, MD

Professor, GI Medical Oncology
MD Anderson Cancer Center, Houston, TX

Michael Pishvaian, MD, PhD

Associate Professor of Oncology
Johns Hopkins University, Washington, DC

Median Overall Survival of First-Line Treatments for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

Featuring:

Featuring:

Related Articles

Stay In The Know

We Value Your Feedback! Tell Us How You Consume Content